Revenue: As of FY2025 Q3, the actual value is USD 60 K.EPS: As of FY2025 Q3, the actual value is USD -0.01.EBIT: As of FY2025 Q3, the actual value is USD -356 K.<h3>Segment Revenue</h3><ul><li>Sales Revenue: Revenue from the sale of LuViva devices and disposables was $60,000 for the three months ended September 30, 2025, compared to none in the prior-year period. For the nine months ended September 30, 2025, revenues were $177,462, compared to $5,720 for the nine months ended September 30, 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: Net loss attributable to common stockholders was $785,445 for the three months ended September 30, 2025, compared to $692,417 in the prior-year period. For the nine months ended September 30, 2025, net loss was $2,103,663, compared to $1,890,970 for the nine months ended September 30, 2024.</li><li>Gross Profit: Gross profit was $34,712 for the three months ended September 30, 2025, compared to none in the prior-year period. For the nine months ended September 30, 2025, gross profit was $113,962, compared to $3,720 for the nine months ended September 30, 2024.</li><li>Operating Expenses: Total operating expenses were $520,000 for the three months ended September 30, 2025, compared to $561,338 in the prior-year period. For the nine months ended September 30, 2025, total operating expenses were $1,775,300, compared to $1,578,476 for the nine months ended September 30, 2024.</li><li>Interest Expense: Interest expense was $129,304 for the three months ended September 30, 2025, compared to $107,500 in the prior-year period. For the nine months ended September 30, 2025, interest expense was $432,752, compared to $246,990 for the nine months ended September 30, 2024.</li><li>Change in Fair Value of Derivative Liability: The change in the fair value of derivative liabilities resulted in a loss of $37,033 for the three months ended September 30, 2025, compared to $585 in the prior-year period. For the nine months ended September 30, 2025, the change in fair value resulted in a gain of $46,227, compared to a loss of $7,935 for the nine months ended September 30, 2024.</li><li>Gain from Forgiveness of Debt: The gain from forgiveness of debt was $15,118 for the three months ended September 30, 2025, compared to $16,145 in the prior-year period. For the nine months ended September 30, 2025, the gain was $46,136, compared to $49,205 for the nine months ended September 30, 2024.</li><li>Loss from Extinguishment of Debt: The loss from extinguishment of debt was $106,200 for the three months ended September 30, 2025. For the nine months ended September 30, 2025, the loss was $138,148.</li><li>Preferred Stock Dividends: Preferred stock dividend expense was $42,837 for the three months ended September 30, 2025, compared to $38,194 in the prior-year period. For the nine months ended September 30, 2025, the expense was $125,875, compared to $126,030 for the nine months ended September 30, 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: Net cash used in operating activities was $776,689 for the nine months ended September 30, 2025, compared to $786,783 in the prior-year period.</li><li>Net Cash Used for Investing Activities: Net cash used for investing activities was $1,797 for the nine months ended September 30, 2025.</li><li>Net Cash Provided by Financing Activities: Net cash provided by financing activities was $477,832 for the nine months ended September 30, 2025, compared to $390,100 in the prior-year period.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The Company is focused on increasing demand for LuViva in the United States, China, and Europe. In the United States, the Company is actively pursuing FDA approval by conducting a clinical trial involving approximately 400 study participants. The study and data analysis are expected to be completed in 2025. In China, the Company is working with its partner SMI to achieve regulatory approval from the NMPA, which is expected in the first half of 2026. The Company has also received sales orders from Turkey and Indonesia, which are expected to result in approximately $200,000 in revenue for 2025.</li><li>Non-Core Business: The Company is in discussions with a new partner to assume the responsibilities formerly under the purview of SMI in China. The Company has also entered into a supply agreement with Hangzhou Dongye Medical Technology Company, Ltd. for the purchase of 35 LuViva devices totaling $700,000.</li><li>Priority: The Company expects to spend approximately $2.3 million to fund the business over the next 12 months, including $425,000 to complete and file the FDA study. Additional expenditures for manufacturing production will be needed only if significant product is ordered and paid for in advance by customers.</li></ul>

Guided Therapeutics, Inc. | 10-Q: FY2025 Q3 Revenue: USD 60 K